Dib A, Barlogie B, Shaugllnessy JD, et al. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma[J]. Blood, 2007, 109(3): 1337-1338.
[2]
Anderson KC. From the guest editor: the evolving treatment paradigm in multiple myeloma[J]. Cancer J, 2009, 15(6): 456.
[3]
Rosenblatt J, Avigan D. Cellular immunotherapy for multiple myeloma[J].Best Pract Res Clin Haematol, 2008, 21(3): 559-577.
[4]
Condomines M, Veyrune JL, Larroque M, et al. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy[J]. J Immunol, 2010, 184(2): 1079-1084.
[5]
Yi Q. Novel immunotherapies[J]. Cancer J, 2009, 15(6): 502-510.
Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Dornor leukocyte infusions are effective in multiple myeloma after allogeneic bone marrow transplantation[J]. Blood, 1997, 90(10): 4206-4211.
[8]
Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited[J]. Cancer Treat Rev, 2010, 36(7): 528-538.
[9]
Klingemann H, Boissel L. Targeted cellular therapy with natural killer cells[J]. Horm Metab Res, 2008, 40(2): 122-125.
[10]
Harnack U, Johnen H, Pecher G. natural killer cell line yt exerts cytotoxicity against CD86+ myeloma cells[J]. Anticancer Res, 2011, 31(2): 475-479.
[11]
Alici E, Konstantinidis KV, Sutlu T, et al. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model[J]. Exp Hematol, 2007, 35(12): 1839-1846.
[12]
Zhong G,Wang J,Xu M,et al. Enhanced maturation and functional capacity of dendritic cells induced by mannosylated L2 domain of ErbB2 receptor[J]. Scand J Immunol, 2005, 62(2):108-116.
[13]
Linn YC, Hui KM. Cytokine-induced killer cells: NK-like T cells with cytotolytic-specificity against leukemia[J]. Leukemia Lymphoma, 2003, 44(9): 1457-1462.
[14]
Eubel J, Enk AH. Dendritic cell vaccination as a treatment modality for melanoma[J]. Expert Rev Anticancer Ther, 2009, 9(11):1631-1642.
[15]
Berntsen A, Trepiakas R, Wenandy L, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial[J]. J Immunother, 2008, 31(8): 771-780.
[16]
Rozkova D, Tiserova H, Fucíkova J, et al. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer[J]. Clin Immunol, 2009, 131(1): 1-10.
Lee JJ, Choi BH, Kang HK, et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates[J]. Leuk Lymphoma, 2007, 48(10): 2022-2031.
[19]
Cohen S, Haimovich J, Hollander N. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma[J]. J Immunol, 2009, 182(3): 1667-1673.
[20]
Pievani A, Belussi C, Klein C, et al. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell(CIK)cultures and anti-CD20 antibodies[J]. Blood, 2011, 117(2): 510-518.
[21]
Zhao Q, Zhang H, Li Y, et al. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro[J]. J Exp Clin Cancer Res, 2010, 29:118-130.
[22]
Gorschlüter M, Ziske C, Glasmacher A, et al. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma[J]. Clin Cancer Res, 2001, 7(8): 2195-2204.
[23]
Lin J, Zhu H, Lu X, et al. Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses[J]. Intern Med, 2010, 49(21): 2341-2346.
[24]
M？rten A, Renoth S, von Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells[J]. Haematologica, 2001, 86(10): 1029-1037.
[25]
Su X, Zhang L, Jin L, et al. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells[J]. J Clin Immunol, 2010, 30(5): 766-774.
Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery[J]. Cytotherapy, 2009, 11(8): 1076-1083.
[28]
Rajkumar SV, Rosiol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma[J]. J Clin Oncol, 2008, 26(13): 2171-2177.
[29]
Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma[J]. Cancer J, 2009, 15(6): 485-493.
[30]
Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs(IMiDS)in multiple myeloma[J]. Leukemia, 2010, 24(1): 22-32.
[31]
Ritchie DS, Quach H, Fielding K, et al. Drug-mediated and cellular immunotherapy in multiple myeloma[J]. Immunotherapy, 2010, 2(2): 243-255.
[32]
Sharabi A, Laronne-Bar-On A, Meshorer A, et al. Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model[J]. Cancer Prev Res(Phila), 2010, 3(10): 1265-1276.
[33]
Sharabi A, Ghera NH. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy[J]. Adv Cancer Res, 2010, 107: 1-37.
Frazier JL, Han JE, Lim M, et al. Immunotherapy combined with chemotherapy in the treatment of tumors[J]. Neurosurg Clin N Am, 2010, 21(1): 187-194.
[36]
Harrison SJ, Cook G, Nibbs RJ, et al. Immunotherapy of multiple myeloma: the start of a long and tortuous journey[J]. Expert Rev Anticancer Ther, 2006, 6(12): 1769-1785.
[37]
Vauleon E, Avril T, Collet B, et al. Overview of cellular immunotherapy for patients with glioblastoma[J]. Clin Dev Immunol, 2010, 2010: 1-18.
[38]
Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma[J]. Hematology Am Soc Hematol Educ Program, 2009: 507-519.
